On this page
What each program costs in Massachusetts
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 6 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 11 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 12 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 13 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 14 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 15 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 16 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 17 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 18 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Massachusetts Group Insurance Commission (GIC) cover GLP-1s for weight loss?
The GIC voted to end coverage of GLP-1s for obesity alone. From July 1, 2026, GIC plans cover them only for diabetes, or for members with a BMI of 27 or higher and an FDA-approved comorbid condition.
Massachusetts Group Insurance Commission
The GIC's FAQ says the Commission voted to eliminate GLP-1 coverage for treating obesity.
“The Commission voted to eliminate coverage for GLP-1 medications for the treatment of obesity.”
https://www.mass.gov/guides/gic-frequently-asked-questions · read Oct 29, 2026
Massachusetts Group Insurance Commission
Obesity-only coverage ended July 1, 2026.
“Coverage will end July 1, 2026 for members using GLP-1s for obesity without an FDA approved comorbid condition.”
https://www.mass.gov/guides/gic-frequently-asked-questions · read Oct 29, 2026
Massachusetts Group Insurance Commission
Coverage continues for diabetes and for a BMI of 27 or higher with an FDA-approved comorbid condition.
“Members with a BMI of 27 or higher and an FDA-approved comorbid condition”
https://www.mass.gov/guides/gic-frequently-asked-questions · read Oct 29, 2026
Does Massachusetts Medicaid (MassHealth) cover GLP-1s for weight loss?
Not covered for weight loss
MassHealth stopped covering Wegovy and Zepbound for obesity or overweight alone on July 3, 2026, and its rule now excludes any drug used for the treatment of obesity or overweight. Read from state documents Nov 6, 2026.
What Massachusetts Medicaid (MassHealth)'s documents say about each drug for weight loss. Read Nov 6, 2026. Massachusetts Executive Office of Health and Human Services, MassHealth.
WegovyNo
Not covered when used only for obesity or overweight. Still approvable with prior authorization for heart disease with BMI above 27, sleep apnea with BMI above 30, or MASH, and for members under 21 when medically necessary under EPSDT.
“Effective July 3, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members when used only for the treatment of obesity or overweight.”
MassHealth Pharmacy Facts, Number 276 (corrected) · Effective Jul 3, 2026 · read Nov 6, 2026
“Wegovy (semaglutide) Zepbound (tirzepatide)”
MassHealth Pharmacy Facts, Number 276 (corrected), Table 1 · Effective Jul 3, 2026 · read Nov 6, 2026
“The MassHealth agency does not pay for any drug used for the treatment of obesity or overweight.”
MassHealth Pharmacy Manual, 130 CMR 406.413(B)(7) · Effective Jul 3, 2026 · read Nov 6, 2026
ZepboundNo
Not covered when used only for obesity or overweight. For the other accepted uses (heart disease, sleep apnea, MASH, or under 21 under EPSDT), Zepbound is no longer preferred and needs a trial of Wegovy first.
“Effective July 3, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members when used only for the treatment of obesity or overweight.”
MassHealth Pharmacy Facts, Number 276 (corrected) · Effective Jul 3, 2026 · read Nov 6, 2026
“Wegovy (semaglutide) Zepbound (tirzepatide)”
MassHealth Pharmacy Facts, Number 276 (corrected), Table 1 · Effective Jul 3, 2026 · read Nov 6, 2026
“The MassHealth agency does not pay for any drug used for the treatment of obesity or overweight.”
MassHealth Pharmacy Manual, 130 CMR 406.413(B)(7) · Effective Jul 3, 2026 · read Nov 6, 2026
OzempicNo
Off-label use for weight loss is not payable, and the rule excludes any drug used for obesity or overweight. The rule's exclusions do not apply to medically necessary therapy for MassHealth Standard and CommonHealth members under 21.
“*Any drug being used off label for weight loss is not payable for MassHealth patients.”
MassHealth Pharmacy Facts, Number 276 (corrected) · Effective Jul 3, 2026 · read Nov 6, 2026
“The MassHealth agency does not pay for any drug used for the treatment of obesity or overweight.”
MassHealth Pharmacy Manual, 130 CMR 406.413(B)(7) · Effective Jul 3, 2026 · read Nov 6, 2026
MounjaroNo
Off-label use for weight loss is not payable, and the rule excludes any drug used for obesity or overweight. The rule's exclusions do not apply to medically necessary therapy for MassHealth Standard and CommonHealth members under 21.
“*Any drug being used off label for weight loss is not payable for MassHealth patients.”
MassHealth Pharmacy Facts, Number 276 (corrected) · Effective Jul 3, 2026 · read Nov 6, 2026
“The MassHealth agency does not pay for any drug used for the treatment of obesity or overweight.”
MassHealth Pharmacy Manual, 130 CMR 406.413(B)(7) · Effective Jul 3, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Massachusetts Executive Office of Health and Human Services, MassHealth documents. KFF's January 2026 map listed this program as covered; the documents we read now say otherwise.
- Jul 3, 2026 · Policy changeEnded coverage of Wegovy and Zepbound when used only for obesity or overweight.
“Effective July 3, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members when used only for the treatment of obesity or overweight.”
MassHealth Pharmacy Facts, Number 276 (corrected) · Effective Jul 3, 2026 · read Nov 6, 2026
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
217,397 prescriptions
Ozempic and Mounjaro, 2025
102,735 prescriptions
Neighbours covering weight loss
0 of 5
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Massachusetts Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Massachusetts Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Massachusetts Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Massachusetts Medicaid pay for?
399,014 GLP-1 prescriptions in 2025, 7th of the 50 states and DC, with $396.7 million reimbursed before rebates. Counting the share other payers covered, $404.5 million.
Prescriptions, 2025
399,014
7th of 51
Medicaid paid
$396.7M
7th of 51, before rebates
Per prescription
$994
$1,051 nationally
Weight-loss brands
54%
7th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Massachusetts is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 54% of Massachusetts Medicaid's GLP-1 prescriptions in 2025 (217,397). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Zepbound was Massachusetts Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Zepboundapproved for weight management | 208,115 | 52% | $212.9 million | $1,023 |
| Trulicity | 75,128 | 19% | $70.6 million | $940 |
| Mounjaro | 61,274 | 15% | $61.7 million | $1,007 |
| Ozempic | 41,461 | 10% | $38.9 million | $937 |
| Wegovyapproved for weight management | 9,167 | 2.3% | $9.4 million | $1,022 |
| Rybelsus | 2,719 | 0.7% | $2.5 million | $933 |
| Victoza | 889 | 0.2% | $539,113 | $606 |
| Liraglutide (generic) | 121 | 0.0% | $58,227 | $481 |
| Saxendaapproved for weight management | 115 | 0.0% | $105,950 | $921 |
| Bydureon | 25 | 0.0% | $19,402 | $776 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in Massachusetts?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 1 in Massachusetts. The register does not say which, if any, supplies a program on this page.
- Fresenius Kabi Compounding LLC dba Fagron Sterile Services, Canton. Registered since Apr 21, 2017; last FDA inspection Nov 5, 2025.
On Medicare in Massachusetts?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Massachusetts and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 5 states next to Massachusetts covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Massachusetts's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Massachusetts | Not covered | 18 | $39/mo |
| Connecticut | Not covered | 19 | $39/moWellmedr |
| New Hampshire | Not covered | 19 | $39/moWellmedr |
| New York | Not covered | 19 | $39/moWellmedr |
| Rhode Island | Not confirmed | 19 | $39/moWellmedr |
| Vermont | Not covered | 19 | $39/moWellmedr |





















